Journal
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
Volume 31, Issue 1, Pages 99-111Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.berh.2017.08.005
Keywords
At risk; Risk stratification; RA prevention; Arthralgia; ACPA
Categories
Funding
- Arthritis Research UK [20525, 19652]
- Medical Research Council UK [G1001516]
- European Commission Innovative Medicines Initiative (BTCURE)
- European Commission Innovative Medicines Initiative (RTCURE)
- Bristol-Myers Squibb [IM101-328]
- MRC [G1001516] Funding Source: UKRI
- Medical Research Council [G1001516] Funding Source: researchfish
- Versus Arthritis [19652, 20525] Funding Source: researchfish
Ask authors/readers for more resources
The field of rheumatology has made major contributions to medicine through the identification of cellular and molecular targets and the development of therapies for the treatment of an impressive range of immune-mediated inflammatory diseases such as rheumatoid arthritis. In recent years, new milestones have been achieved. These include the recognition of an at-risk state, characterized by disease specific autoantibodies in serum and inflammatory joint pain, and the initiation of studies seeking to prevent high-risk individuals from progressing to a state of clinically apparent arthritis. Here, the current state of the art of rheumatoid arthritis prevention is described, highlighting the importance of risk stratification and reporting on a growing portfolio of therapeutic interventions targeting different stages of the preclinical syndrome. Crown Copyright (C) 2017 Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available